Bibliographic Details
| Title: |
Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay. |
| Authors: |
Rico, María J., Perroud, Herman A., Herrera, Cintia, Alasino, Carlos M., Roggero, Eduardo A., Pezzotto, Stella M., Nocito, Ana Lía, Rozados, Viviana R., Scharovsky, O. Graciela |
| Source: |
Cancer Investigation; 2017, Vol. 35 Issue 6, p377-385, 9p |
| Subject Terms: |
BREAST cancer treatment, BIOMARKERS, CANCER immunotherapy, CANCER stem cells, HEALTH outcome assessment |
| Abstract: |
Identifying tumor biomarkers associated with clinical behavior in breast cancer patients may allow higher accuracy in the selection of treatment. Different types of cells were determined in the primary tumors of stage I, II, and III of breast cancer patients, who were assigned to one of the two groups: (1) disease-free or (2) relapsed/progressed, at 5 years after primary treatment. We studied 32 tumor samples. CD4+lymphocytes and CD44+CD24−/lowcells (cancer stem cells) showed a significant association with clinical outcome at 5 years of primary treatment, while CD8+, Foxp3+, CD34+, and myeloid-derived suppressor cells did not show any association. Coincident with the results of individual analysis, we identified CD4+cells and CD44+CD24−/lowcells as good predictors of long-term clinical outcome in a logistic regression. [ABSTRACT FROM PUBLISHER] |
|
Copyright of Cancer Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
